,
2 min read
The region continues to emerge as an increasingly strategic landscape for life sciences expansion. Regulatory cooperation initiatives across LATAM illustrate how health authorities are enhancing collaborative frameworks that may support greater regulatory alignment. One example is the agreement between ANVISA (Brazil) and COFEPRIS (Mexico), which highlights ongoing efforts to advance regulatory reliance and international regulatory convergence in the region. For companies seeking entry into both Brazil and Mexico, these reliance mechanisms may influence regulatory planning, particularly in areas such as GMP certification recognition, regulatory inspection strategies, and potential expedited pathways for certain product categories. . As pharmaceutical markets across LATAM continue to expand, regulators are increasingly exploring mechanisms that promote cooperation and efficiency while preserving independent regulatory decision-making and national oversight.
ANVISA–COFEPRIS Cooperation: Advancing Regulatory Alignment in LATAM
In 2025, ANVISA announced strengthened regulatory cooperation with COFEPRIS, reinforcing collaboration between the two agencies in areas such as:
- Exchange of regulatory information
- Cooperation between regulatory systems
- Recognition of regulatory practices
- International regulatory collaboration
These initiatives align with ANVISA’s broader efforts to promote regulatory reliance, a regulatory approach that allows authorities to consider evaluations, inspections, or regulatory decisions from trusted international regulators while maintaining independent regulatory decision-making. Regulatory reliance has gained global attention as authorities seek ways to improve regulatory efficiency without compromising regulatory standards. In LATAM, cooperation between key regulatory authorities such as ANVISA and COFEPRIS may represent an important step toward strengthening regulatory systems and encouraging greater regulatory alignment across the region.
Why regulatory cooperation matters for the industry
For pharmaceutical, biotechnology, and life sciences companies operating across LATAM, increased regulatory cooperation may offer several potential benefits. Greater collaboration between health authorities may contribute to:
- Improved regulatory alignment between key regional markets
- More efficient regulatory pathways and submission strategies
- Improved predictability in regulatory processes
However, evolving regulatory frameworks may also require companies to continuously adapt their documentation strategies, regulatory planning and intelligence capabilities to remain aligned with changing expectations. Organizations operating across multiple jurisdictions in LATAM increasingly need to understand how regulatory convergence initiatives may influence regulatory processes and timelines.
A signal of evolving regulatory collaboration in LATAM
As LATAM continues to position itself as a region of regulatory and market expansion, initiatives such as the ANVISA–COFEPRIS cooperation agreement may offer an early signal of how regulatory collaboration could evolve in the coming years. Questions increasingly relevant for the industry include:
- Could regulatory cooperation agreements become more common across LATAM?
- Will additional authorities adopt reliance-based approaches?
- How might regulatory convergence influence market entry strategies in the region?
Monitoring these developments can help organizations anticipate regulatory trends and strengthen regulatory strategies across Brazil and the broader LATAM region. Understanding emerging regulatory collaboration initiatives is increasingly important for companies operating across complex regulatory environments. Freyr supports life sciences organizations in interpreting regulatory developments across Brazil and LATAM, helping companies translate regulatory insights into informed regulatory strategies aligned with both global objectives and local regulatory requirements.
Connect with Freyr’s regulatory experts to explore how regulatory reliance initiatives may influence your regulatory strategy across LATAM.
